

Subject Index

A

Acetol and glucose oxidation, 450
Acetone and glucose oxidation, 450
Adenosine, insulin action, 62
Adenylate cyclase activation, 875
Adoptive transfer, 928
Aging, fluorescence as marker for pathologies, 796
 α -Agonists, sensitivity to, 1289
Albumin
 permeation, 312, 323
 transcapillary escape rate, 919, 1212
 see also Urinary albumin excretion
Albuminuria
 enalapril effects, 1575
 proteoglycan production decrease, 196
 thrombomodulin levels and nephropathy, 983
 see also Microalbuminuria
Aldose reductase inhibitor
 motor nerve conduction velocity, 663
 neuropathy, 690
 autonomic, 613
 rutin, prevention of age-related pathologies, 796
Amino acid
 effect on glucose disposal, 1079
 replacement, 376
 residues, 118
 transport, 570
Aminoguanidine, prevention of age-related pathologies, 796
Amylin
 insulin resistance, 260
 meal ingestion effects, 752
Amyloid, islet, formation, 118
Angiogenesis, inhibitory activity, 12
Antigen expression, 697
Aqueous humor, 12
Arachidonic acid, 914
Arterioles, 354
Atherogenesis, insulinlike growth factor I, 657
Atherosclerosis
 and hyperinsulinemia, 1527
 nonenzymatic glycosylation of lipoproteins, 1257
Atrial
 natriuretic factor, 483
 peptide, 289
 structure, 483

B

Bacitracin effect on insulin degradation, 1339

Basement membranes

 alterations after nonenzymatic glycosylation, 807
 endoneurial capillary thickening, 909
 type IV collagen production, 196, 885
Black Americans, genetic analysis of susceptibility, 49, 1534
Blastocysts, inner cell mass changes, 471
Blood
 flow
 cerebral, 1040
 fetal hypotrophy, 743
 glucose metabolism, 437
 kinetics of glucose uptake, 955, 965
 pressure and urinary albumin excretion, 245
 volume and transcapillary albumin escape rate, 919
 withdrawal, effect on lymphopenia, 1099
 see also Hypertension
Body fat distribution, predictor in Mexican Americans, 283
Bone metabolism, 477
Brain stem impairment and hypoglycemia, 1550
Browning, nonenzymatic, 57

C

Ca²⁺

-ATPase activity
 glycosylation of erythrocyte membrane, decreased, 707
 transport, 850
-channels, voltage-sensitive and cardiomyopathy, 1064
 influx in β -cells, 1457
 mobilization changes in non-insulin-dependent diabetes, 1561
Calcitonin gene-related peptide, 168, 260
Candida albicans, 271
Captopril effects on urinary albumin excretion rate, 1333
Carbohydrates, postprandial metabolism and insulin delivery, 142
Cardiac autonomic function, measurement of heart-rate variability, 1177
Cardiomyopathy and voltage-sensitive Ca²⁺ channels, 1064
Cardiorespiratory reflexes, effect of pancreas transplantation, 802

α -Cells

 major histocompatibility complex, 415
 physiology, 407

β -Cells

 antigen expression, 697
 defect and obesity-induced diabetes, 1050
 desensitization and insulin secretion, 1581
 destruction, autoimmunity studies, 590, 1273
 glucose-induced electrical activity, 1457
 insulin secretion signaling mechanism, 1461

islet

 amyloid polypeptide and insulin secretion, 634
 transplantation, 401
major histocompatibility complex, 415, 1125
nonprogressive subclinical dysfunction, 549
pancreas transplantation, 534
pancreatic, glucokinase as glucose sensor, 647
sulfated cholecystokinin-8 effects, 702
T lymphocyte
 -induced destruction, 928
 receptor effect, 975

Cerebral glucose metabolism, 175

Children, insulin-dependent diabetes cyclosporin and remission, 1264
incidence trends, 858
islet cell antibodies as predictive marker, 1144
Chinese, non-insulin-dependent diabetes prevalence, 390
Cholecystokin-8 effects on insulin secretion, 702

Cholesterol

 metabolism in diabetic rabbits, 626
 reduced membrane fluidity, 241

Cholinergic nerve, 891

Chromatin structure, 348

Collagen
 fluorescence as marker for age-related pathologies, 796
 type VI, 31, 196, 885
Converting-enzyme inhibition, glomerular barrier function, effect on, 76
C-peptide levels
 concentrations after onset, 653
 elevated fasting and prevalence, 104
 remission from insulin dependency, 768
 retinopathy, 1445

DIABETES: VOLUME 39 (1990) PAGE NUMBERS BY ISSUE

January, 1-128
February, 129-269
March, 271-399

April, 401-522
May, 523-645
June, 647-759

July, 761-877
August, 879-1007
September, 1009-1152

October, 1153-1314
November, 1315-1460
December, 1461-1587

Creoles, non-insulin-dependent diabetes prevalence, 390
Cyclosporin
 allograft survival, with UV light, 305
 immunosuppression monitoring, 204
 insulin-dependent diabetes remission in children, 1264
 pancreatic events, effect on, 508
 remission from insulin dependency, 768
 Shwartzman reaction, 82
Cytokine, effect on pancreatic islet cells, 415

D

Diacylglycerol, 181, 667
Diabetic feet. See **Foot, diabetic**
Diet
 high fat, 226
 incidence of diabetes, 432
 obese pregnant women, 234
Dogs
 hepatic glucose uptake, 87
 insulinlike growth factor I and insulin effects, 340
 intravenous glucose sensor, 1519
 portal insulin absorption, 1361

E

Enalapril effects
 glomerular barrier function, 76
 hypertension, 1575
Enzyme regulation, 523
Enteric nervous system, 891
Erythrocyte
 fetal, effect on glucose homeostasis, 1191
 membranes, Ca^{2+} -ATPase activity after glycosylation, 707
 -type glucose transporter, 1543
Exercise
 diabetic feet, 938
 increase in glucose transporters, 1425
 -induced urinary albumin excretion rate, captopril effects, 1333

F

Fat
 intra-abdominal and non-insulin-dependent diabetes prevalence, 104
 oxidation, 22
Fatty acids
 free
 glucose oxidation and hypoglycemia, 134
 inhibition of insulin binding, 570
 Randle's cycle, 383

ω-3
 marine lipids, 426
 vascular risk factors, 368
Fetal
 hyperinsulinemia, 541
 hypotrophy, 743
Fibroblasts
 estimating initial glucose uptake rate, 1228
 growth factor mitotoxins, 1002
 nonenzymatic glycosylation of lipoprotein effect on binding, 1257
FK 506 effects, 1585
Foot, diabetic, exercising and medial arterial calcification, 938
Freund's adjuvant, 583

G

Galactosemic cataract formation, 1347
Gangliosides, 782
Genetics
 gene
 expression affected by insulinlike growth factor, 1490
 structure, 523
 HLA associations, 1153, 1504
 susceptibility
 Black Americans, 49, 1534
 HLA-DQ β sequence, 96
 HLA-DR haplotypes, 1138
 mapping, 1315
 streptozocin-induced diabetic mice, 1298
 Welsh patients, 1479
 transcription, insulin accumulation, 683
 see also **Insulin receptor**
Gestational
 diabetes mellitus, diet in obese women, 234
 hyperglycemia, 734
Glomerular
 barrier function, enalapril effects, 76
 basement membrane, measurement, type VI collagen, 31
 filtration rate
 exchangeable sodium, vasoactive hormones and insulin therapy, 1182
 islet isografts effects, 323
 reversal by blood glucose normalization, 989
 hyperfiltration, 989
 volume and nephropathy, 1057
 myo-inositol effects, 312
Glucagon
 amino acid replacement effects, 376
 insulinlike growth factor I effects, 340
 posttranslational processing, 406
 release
 homologous galanin effects, 996
 inhibition of, 1320

Glucose
 basal production impaired, 597
 cerebral metabolism, 175
 clearance, 211, 340
 cycling, 456
 delivery
 increased and postprandial hyperglycemia, 1381
 routes, 87
 disposal
 amino acid effects, 1079
 insulin effect in skeletal muscle, 1106
 oral glucose ingestion, 747, 775
 glucokinase as sensor, 647
 homeostasis
 fasting, refeeding, diabetes and insulin effects, 712
 fetal erythrocyte effects, 1191
 regulation of, 523
 sensitivity to κ -agonists, 1289
 vanadate effects, 1326
 -induced
 electrical activity in β -cells, 1457
 increase in diacylglycerol, 667
 insulin secretion, 1170, 1461
 ingestion rate and insulin economy, 775
 intravenous sensor (dogs), 1519
 islet amyloid polypeptide response to, 639
 levels
 glycosylation of erythrocyte membranes, 707
 insulin secretion, 397
 normalization effects, 989
 predictor in Mexican Americans, 283
 sulfated cholecystokinin-8 effects, 702
 metabolism
 impaired in skeletal muscle, 1106
 increased and postprandial hyperglycemia, 1381
 reduction, 437
 oxidation
 acetone and acetol inhibition, 450
 hyperglycemia, 149
 hypoglycemia, 134
 insulin effects, 1373
 lipoprotein modification, 1420
 stimulation of, 22
 placental flux, 276
 production
 insulinlike growth factor I and insulin effects, 340
 negative, 217
 Randle's cycle, 383
 recovery and amino acid replacement, 376
 resistance and impaired glucose metabolism, 1106
 sensing, glucokinase, 647
 stimulation of insulin release, 1320
 tolerance
 gestational hyperglycemia, 734

DIABETES: VOLUME 39 (1990) PAGE NUMBERS BY ISSUE

January, 1-128
 February, 129-269
 March, 271-399

April, 401-522
 May, 523-645
 June, 647-759

July, 761-877
 August, 879-1007
 September, 1009-1152

October, 1153-1314
 November, 1315-1460
 December, 1461-1587

impaired
effect on lipoprotein structure, 1527
non-insulin-dependent diabetes
prevalence, 390, 1131

transport
cerebral blood flow, 1040
erythrocyte type and muscle/fat type, 1543
exercise effects, 1425
fibroblasts used to estimate rate, 1228
genes, 6, 49, 1534
glucose oxidation, 1373
insulin effects, 181
insulinlike growth factor I stimulation, 1028
liver protein and mRNA, 441
rate-limiting defect for disposal, 157
skeletal muscle, 865, 1425
two species in liver, 712

uptake
hyperglycemia effect on, 149
hyperinsulinemia effects, 490
kinetics, 955, 965
muscle insulin resistance, 211
postoperative patients, 747
stimulation of, 22
sulfonylurea effects, 1399

Glyburide effects on glucose uptake, 1399

Glycemic control, retinal blood flow, 602

Glycogen, insulinlike effects of vanadate on, 821

Glycosylation
advanced end product receptor, 1510
autoxidative, 1420
erythrocyte membranes, Ca^{2+} -ATPase activity, 707
nonenzymatic, 57
lamina alterations, 807
lipoproteins and atherosclerosis, 1257

Growth factor I. See Insulinlike growth factor I

Growth hormone. See Insulinlike growth factor I

H

Heart
rate variability, 613, 1177
transplantation, 740

Hemoglobin, glycosylated
labile, 17
removal from blood samples, 17

Hepatic glucose output
adenosine effects, 62
impaired basal regulation, 597
production inhibited by SDZ 51641, 1408
uptake, insulin and glucose delivery route, 87

Hepatocytes
free-fatty acid effects, 570
glucokinase, 647

HepG2/erythrocyte glucose-transporter gene, 49

Hexose distribution volume, 175

HLA
DQ β -chain
aspartic acid at position 57, 266
genetic susceptibility, 96

DP variation as risk factor, 855

DR
haplotype, genetic susceptibility, 1138
phenotype, remission monitoring, 204

gene associations with insulin-dependent diabetes, 1153, 1504

Human
growth hormone, 1045
insulin and insulin analogues, 1033
proximal tubule cell response to hyperglycemia, 949

Hyperfiltration, 299, 989

Hyperglycemia
calcitonin gene-related peptide, 168
 β -cell desensitization and insulin secretion, 1581
cerebral blood flow, 1040
fat metabolism, effect on, 22
gestational, 734
glucose uptake, effect on, 149
inducement by fat feeding, 226
infections, 271
insulin secretion, 1436
myo-inositol, 575
postprandial, increased systemic glucose delivery, 1381

Hyperinsulinemia
and atherosclerosis, 1527
fat metabolism, effect on, 22
fetal, 541
increased transcapillary escape rate of albumin, 1212
pancreas transplantation, 534
pulsatile, prolonged, 500
sex and obesity effects on, 789

skeletal muscle
contraction changes, 460
metabolism, 490

Hypertension
insulin, 1430
insulin-dependent diabetes, 1556
nephropathy, 1575

Hypoglycemia
activation of polyol pathway, 949
amino acid replacement, 376
brain stem impairment, 1550
cerebral glucose metabolism, 175
cognitive dysfunction, 828
glucose oxidation, 134
hexose distribution volume, 175
human and pork insulin effects on, 1091
see also Oral hypoglycemic agents

Hypoxia in ventricular papillary muscles, 1485

I

IDDM. See Insulin-dependent diabetes mellitus

Indians, non-insulin-dependent diabetes prevalence, 390

myo-Inositol
depletion hypothesis, 1305
glomerular filtration changes, 312
hyperglycemia, 575
motor nerve conduction velocity deficit, 663

Insulin
absorption, 1361
accumulation effects, 683
action
free-fatty acid inhibition, 570
in vivo, 333, 528
mice, 563
regulating cell growth and gene transcription, 683
skeletal muscle metabolism, 490
aggregates, 728
allergy, 728
analogues, 1033
antibodies, remission monitoring, 204
Asp 57 hypothesis, 266
autoantibodies, 720
binding, 570
clearance, 333
cyclosporin and remission from dependency, 768
degradation, 570, 1339
delivery, 87
peritoneum cavity method, 1361
portal and peripheral effects, 142
dependency remission, 768
economy, 775
englitazone effects on hypoglycemia, 1218
exercise effects, 1425
fasting level as predictor in Mexican Americans, 283
gene expression impaired in obese rates, 1050
glucoregulation, effect on, 340
glucose
impaired metabolism in skeletal muscle, 1106
oxidation, 450, 1373
transport, effect on, 181
turnover, 217

HLA-DP variation as risk factor, 855

human
effects on hypoglycemia, 1091
insulin analogues, 1033
hypertension, 1430
independence after islet transplantation, 515, 519
islet amyloid polypeptide response to, 639

DIABETES: VOLUME 39 (1990) PAGE NUMBERS BY ISSUE

January, 1-128	April, 401-522	July, 761-877	October, 1153-1314
February, 129-269	May, 523-645	August, 879-1007	November, 1315-1460
March, 271-399	June, 647-759	September, 1009-1152	December, 1461-1587

kinetics
 glucose uptake, 955, 965
 insulin analogues, 1033
leucine metabolism, effect on, 38
mimetic agents, 1, 757, 821, 1243, 1326
nuclear effects, 683
pharmacokinetics, 563
pork, effects on hypoglycemia, 1091
pyruvate dehydrogenase sensitivity, 361
regulator of growth hormone, 1251
remission, monitoring, 204
replacement and sex behavior, 942
resistance
 adenosine effects, 62
 calcitonin gene-related peptide, 260
cell surface alterations, 924
glucose-transporter genes, 6
glucose turnover, 217
insulin-receptor gene, 123, 129, 250
sex and obesity effects on, 789
skeletal muscle, 865, 1106
retroendocytosis, bacitracin effects, 1339
secretion
 β -cell, 634, 1461, 1581
glucokinase inactivation effects, 1170
glucose
 cycling increase, 456
 stimulation of release, 1320
gestational hyperglycemia, 734
high glucose levels, 397
homologous galanin effects, 996
hyperglycemia, 226, 1436
ion-channel activity, 1353
islet amyloid polypeptide, effect of, 871
pulsatile in rat islets, 112
stimulated by islet cell-stimulating antibodies, 1165
sulfated cholecytokinin-8 effects, 702
sensitivity
 glucose ingestion rate, 775
 prolonged pulsatile hyperinsulinemia, 501
therapy
 glomerular filtration rate, 1182
 intensive and hypoglycemia, 134
lipoproteins, effect on, 1017
 prophylactic, 933
 sodium retention, 289
tyrosine effects, 528
Insulin-dependent diabetes mellitus
 antigen expression, 697
 children
 cyclosporin and remission, 1264
 incidence trends, 858
 islet cell antibodies as predictive marker, 1144
 complications prevalence, 1116
C4b-binding protein level, 447
FK 506 effects, 1585
genetic mapping, 1315

glucose disposal in skeletal muscle, 157
HLA gene associations, 1153, 1504
hypertension, 1556
hypoglycemia, 134
insulin
 action and clearance, 333
 autoantibodies, 720
 remission from dependency, 768
 interleukin 2 receptors impaired, 1070
 islet cell antibodies, 549, 653, 1085, 1144
 islet transplantation, 515, 519
 leucine metabolism, 38
 lipoprotein subfraction composition, 1158
microalbuminuria
 development of, 245
 nephropathy detection, 761
 ω -3 fatty acid effects, 369, 426
pancreas transplantation, 534, 1235
pathogenesis of, 879
pregnancy, arachidonic acid, 914
prevention (position statement), 1151
prevention in mice
 Freund's adjuvant, 583
 prophylactic insulin therapy, 933
protein S deficiency, 447
retinopathy and glycemic control, 602
susceptibility, 96, 1138
Insulin-like growth factor I
 atherogenesis, 657
 glucoregulation, effects on, 340
 human skeletal muscle, 1028
 insulin as regulator, 1251
 kidney enlargement, 557
 receptor concentration, 1490
 retinopathy, 191
Insulin receptor, 1009
 anti-idiotypic antibodies, 1467
 binding/reduction, 501
gene
 development of diabetes, 129
modular, 1009
non-insulin-dependent diabetes in Welsh patients, 1479
partial sequence, 123
kinase
 activity, 1011
 autophosphorylation in human adipocytes, 250
streptozocin-induced effects, 619
localization and decreased microvilli, 924
structure and function, 1010
Interferon- γ , major histocompatibility complex, 415, 1125
Interleukin 1, major histocompatibility complex, 415
Interleukin 2 receptors, 1070
Ion channels and insulin secretion, 1353
Islet
 amyloid polypeptide
 adenylate cyclase activation, 875
 cat, structure, 118

β -cells, 634
insulin secretion, effect on, 870
response to glucose and insulin, 639
cell
 antibodies, 204, 549, 653, 1085, 1144, 1203, 1366
 antigens, 653
 replication, 70
 β -stimulating antibodies effect on insulin secretion, 1165
 transplantation, prolongation, 305
hormone secretion after β -cell transplantation, 1235
isografts, 323
transplantation
 autoimmune destruction, 643
 insulin independence, 515, 519
mass and function, 401

J

Japanese Americans
Asp 57 hypothesis, 266
prevalence of non-insulin-dependent diabetes, 104

K

K^+ channels, high glucose levels, 397
Kallikrein activity, 299
Ketonemia/ketonuria, 234
Kidney
 function, 299
 growth, 557
insulin-like growth factor receptors, 1490

L

Lactogenic receptors, 1045
Laminin, 807
Learning and memory, 1391
Leprechaunism, 924
Leucine
 β -induced insulin secretion, 1461
 metabolism, 38
Lipoproteins
 glycosylation and peroxidation, 1420
 insulin therapy effects, 1017
 ω -3 fish oils, effects of, 426
 reduced membrane fluidity, 241
subfraction composition differences, 1158
structural abnormality, resonance Raman spectroscopy, 1451
tumor necrosis factor, 1569
Lithium, insulin-mimetic effects of, 1243
Lymphopenia, effects of blood withdrawal, 1099
Ly-6C, expression by T lymphocytes, 815

DIABETES: VOLUME 39 (1990) PAGE NUMBERS BY ISSUE

January, 1-128	April, 401-522	July, 761-877	October, 1153-1314
February, 129-269	May, 523-645	August, 879-1007	November, 1315-1460
March, 271-399	June, 647-759	September, 1009-1152	December, 1461-1587

M

Macrophages
β-cell destruction development, 1273
receptor system, 1510
Major histocompatibility complex
class II expression inhibited, 1125
cytokine effects on pancreatic islet cells, 415
Maternal diabetes, 276
Mauritians, non-insulin-dependent diabetes prevalence, 390
Medial arterial calcification, 938
Membrane fluidity
lipoprotein cholesterol concentration, 241
polymorphonuclear leukocytes, 466
Memory and learning, 1391
Metformin effect on insulin metabolism, 844
Mexican Americans, predictors of non-insulin-dependent diabetes, 283
Mice
coxsackievirus-infected, food intake, 675
displacement of monoclonal antibodies, 1203
insulin action, 563
major histocompatibility complex, 415, 1125
nonobese diabetic (NOD)
anti-islet cell antibodies, 1366
CD3-complex stimulation of T lymphocytes, 815
diet effects, 432
Freund's adjuvant, 583
interleukin 2 receptors impaired, 1070
islet antigen antibodies, 1085
macrophages in β-cell destruction, 1273
prophylactic insulin therapy, 933
T-lymphocyte-receptor effects, 975
ob/ob
effects of CP 68722, 1218
sensitivity to κ-agonists, 1289
vanadate effects, 1326
streptozocin-induced diabetic genetic susceptibility, 1298
learning and memory, 1391
thromboxane synthase inhibition, 196
transgenic
glucagon processing, 406
model of insulin-dependent diabetes, 879
Microalbuminuria
development of, 245
nephropathy detection, 761
Mineral metabolism, 477
Muscle
glucose transporter, 1543
insulin resistance, 211
postprandial hyperglycemia, 1381
skeletal
contraction changes, 460

glucose
disposal, 157
exercise effects, 1425
transport, 865
insulin-like growth factor I effects, 1028
metabolism, insulin effects, 490, 1106
ventricular papillary, action potential duration, 1485
Mutation *db*, 675

N

Natural killer cell cytotoxicity, 590, 836
Na⁺-Ca²⁺ transport, 850
Na⁺-K⁺-ATPase activity
ganglioside treatment effect, 782
kinetics of ATP hydrolysis altered, 1472
motor nerve conduction velocity, 663
transport, 850
Nephropathy
early stage, captopril effects, 1333
enalapril effects, 76
glomerular volume, 1057
hypertension, 1575
kallikrein activity, 299
microalbuminuria follow-up as
detection, 761
thrombomodulin levels, 983
Nerve
cholinergic, 891
conduction
pancreas transplantation, effect on, 802
velocity, 608, 663
degeneration and regeneration, 898
Neuropathy
autonomic
aldose reductase inhibitor, 690
effect of pancreas transplantation, 802
elemental and water distribution, 1498
endoneurial capillary abnormalities, 909
pain, 898
polyol-pathway flux, 663
vasoactive intestinal polypeptide content, 608
NIDDM. See Non-insulin-dependent diabetes mellitus
Nifedipine effects on urinary albumin excretion rate, 1333
Non-insulin-dependent diabetes mellitus
etiology, model for study, 226
genetic
analysis, 49, 1534
mapping, 1315
glucose
clearance, 211

increased basal production, 597
negative production, 217
oxidation decreased, 1373
transport in skeletal muscle, 865
hyperglycemia
effects on glucose uptake, 149
postprandial, increased systemic glucose delivery, 1381
insulin
obesity and metformin effects, 844
resistance, 250, 260
therapy effect on lipoproteins, 1017
insulin-like growth factor I resistance, 1028
islet amyloid polypeptide, 634
lipoprotein structure, effect on, 1527
meal ingestion effects on amylin concentration, 752
oral hypoglycemic agent CP 68722, 1281, 1414
pathogenesis, model for study, 226
platelets, enhanced aggregation, 1561
prevalence in
adult population in Wadena, MN, 1131
Chinese, 390
Creoles, 390
Indians, 390
Japanese Americans, 104
Mauritians, 390
Mexican Americans, predictors, 283
Randle's cycle, 383
somatostatin concentrations, fasting and postprandial, 1198
susceptibility
Black Americans, 49, 1534
Welsh patients, 1479
Norepinephrine
turnover and insulin replacement, 942
vascular reactivity, 354

O

Obesity
β-cell defect, 1050
insulin
hypertension, 1430
metabolism
effect on, 789
metformin effects, 844
insulin-like growth factor I resistance, 1028
kinetics of glucose uptake, 965
lipoprotein structure, effect on, 1527
predictor in Mexican Americans, 283
pregnant women, 234
Oral hypoglycemic agents
CP 68722, 1218, 1414
SDZ 51641, 1408
Osteoporosis, 477
Oxidative stress, 1347, 1420

DIABETES: VOLUME 39 (1990) PAGE NUMBERS BY ISSUE

January, 1-128
February, 129-269
March, 271-399

April, 401-522
May, 523-645
June, 647-759

July, 761-877
August, 879-1007
September, 1009-1152

October, 1153-1314
November, 1315-1460
December, 1461-1587

P
 Pain and neuropathy, 898
 Pancreas
 cyclosporin effects on, 508
 fibroblast growth factor mitotoxin effects, 1002
 islet cells
 major histocompatibility complex, 415
 natural killer cell cytotoxicity, 836
 transplantation
 cardiorespiratory reflexes, effect of, 802
 hyperinsulinemia, 534
 nerve conduction, effect of, 802
 stimulation of islet hormone secretion, 1235
 Pima Indians, insulin and hypertension, 1430
 Platelets
 enhanced aggregation in non-insulin-dependent diabetes, 1561
 reduced membrane fluidity, 241
 Polycystic ovarian disease, 361
 Polyol pathway
 activation under hyperglycemic conditions, 949
 myo-inositol -depletion hypothesis, 1305
 neuropathy, 663
 inhibition of and autonomic, 613
 skeletal muscle contraction, 460
 Polyphosphoinositide turnover changes in non-insulin-dependent diabetes, 1561
 ganglioside treatment effect, 782
 Pregnancy
 arachidonic acid, 914
 gestational hyperglycemia, 742
 inner cell mass changes, 471
 obese women, 234
 Protein
 kinase C
 glucose effects, 667
 insulin effects, 181
 sulfonylurea effects, 1399
 phosphorylation
 changes in non-insulin-dependent diabetes, 1561
 ganglioside treatment effect, 782
 S, acquired deficiency, 446
 turnover, 541
 Proteoglycan, production decrease and albuminuria, 196
 Puberty, effect on kidney growth, 557
 Pyruvate dehydrogenase, 361

R
 Rabbits
 aqueous humor, 12
 cholesterol metabolism, 626
 Randle's cycle, 363

Rats
BB
 adoptive transfer by T lymphocytes, 928
 autonomic neuropathy, 613
 bone and mineral metabolism, 477
 FK 506 effects, 1585
 insulin autoantibodies lacking, 720
 islet transplantation, 519
 lymphopenia, blood withdrawal effects, 1099
 natural killer cell cytotoxicity, 836
 silica treated, 590
BB/Edinburgh
 anti-idiotypic antibodies, 1467
 cyclosporin effects, 508
BB/Wor
 islet destruction, 643
 RT6 alloantigen, 1279
 fetal hyperinsulinemia, 541
 hepatocytes, free-fatty acid effects, 570
 hyperglycemia, 168
 myo-inositol uptake, 575
 insulin
 effects, 181
 sex and obesity effects, 789
 Lewis, antigen expression, 697
 pancreas
 cyclosporin effects, 508
 high glucose levels, 397
 homologous galanin effects, 996
 islets, glucose cycling, 456
 pulsatile insulin secretion, 112
 thymidine kinase activity, 70
 phosphorytyrosine-containing proteins, 528
 placental transfer, 276
 protein turnover, 541
 Schwartzman reaction, 83
 Sprague-Dawley
 β -cell desensitization and insulin secretion, 1581
 glucose
 hepatic production inhibited, 1408
 induced diacylglycerol increase, 667
 transporters, 712, 1543
 growth factors in aorta, 657
 insulin secretion and ion-channel studies, 1353
 islet amyloid polypeptide, 634, 871, 875
 lithium effects, 1243
 vanadate effects, 821, 1243
 Wistar
 fetal erythrocytes effect on glucose homeostasis, 1191
 galactosemic cataract formation, 1347
 hyperglycemia
 fat feeding, 226
 gestational, 734
 insulin secretion, 1436

impaired β -cells and obesity, 1050
 kinetics of ATP hydrolysis, 1472
 lactogenic receptors on β -cells, 1045
 prevention of age-related pathologies, 796
 sulfated cholecystokinin-8 effects, 72
 Zucker, impaired β -cells and obesity, 1050
 see also Streptozocin-induced diabetes mellitus
 Resonance Raman spectroscopy, 1451
 Retinopathy
 C-peptide, 1445
 glycemic control and blood flow, 602
 insulinlike growth factor I, risk factor, 191
 Rutin, prevention of age-related pathologies, 796

S
 Sex
 as factor in complications prevalence, 1116
 behavior and insulin replacement, 942
 effect on insulin metabolism, 789
 Schwartzman reaction, cyclosporin effect, 83
 Sodium retention, 289
 Somatostatin
 concentrations in non-insulin-dependent diabetes, 1198
 secretion, homologous galanin effects, 996
 Streptozocin-induced diabetes mellitus mice
 genetic susceptibility, 1298
 learning and memory, 1391
 rats
 aldose reductase inhibitors, 690
 atrial structure, 483
 blood glucose metabolism, 437
 normalization effects, 989
 cholinergic nerve, 891
 embryopathy, inner cell mass, 471
 enalapril effects on hypertension, 1575
 fetal hypotrophy, 743
 ganglioside treatment effect, 782
 glomerular filtration rate, 312, 323, 1182
 glucose transport in skeletal muscle, 865
 insulin
 effect on glucose utilization, 1106
 glucose dependency of release, 1320
 kidney
 function, 299
 growth, 557
 liver glucose-transporter protein, 441
 membrane fluidity, 466

DIABETES: VOLUME 39 (1990) PAGE NUMBERS BY ISSUE

January, 1-128	April, 401-522	July, 761-877	October, 1153-1314
February, 129-269	May, 523-645	August, 879-1007	November, 1315-1460
March, 271-399	June, 647-759	September, 1009-1152	December, 1461-1587

neuropathy, elemental and water distribution, 1498
norepinephrine effects, 354
pancreatic islets, glucose cycling, 456
prevention of age-related pathologies, 796
sexual behavior and insulin replacement, 942
skeletal muscle contraction, 460
vanadate effects, 1, 757, 821
vasoactive intestinal polypeptide content, 608
ventricular papillary muscles, action potential duration, 1485
Wistar, transcapillary albumin escape rate, 919
Zucker, insulin-receptor tyrosine kinase activity, 619

T

Thrombomodulin levels and nephropathy, 983
Thromboxane
beneficial changes of vascular risk factors, 368

synthase inhibition, 196
Thymidine kinase, 70
T lymphocytes
adoptive transfer, 928
CD3-complex stimulation, 815
interleukin 2 receptors impaired, 1070
Ly-6C expression, 815
macrophage-dependent decrease, 590
pyruvate dehydrogenase sensitivity, 361
receptor effects on β -cell, 975
RT6 alloantigen, 1279
Tolbutamide effects on glucose uptake, 1399
Transcapillary escape rate, 919, 1212
Tumor necrosis factor, increased lipoprotein and triglyceride, 1569
Type I diabetes. See Insulin-dependent diabetes mellitus
Type II diabetes. See Non-insulin-dependent diabetes mellitus
Tyrosine kinase activity in obese Zucker rats, 619
phosphorylated proteins, 528
Tumor necrosis factor, major histocompatibility complex, 1125

U

Urinary albumin excretion
blood pressure, relationship with, 245
captopril effects, 1333
see also Microalbuminuria
UV light, prolongation of allograft survival, 305

V

Vanadate, insulin-mimetic effects, 1
amylase activity normalized, 757
glucose homeostasis improved, 1326
glycogen metabolism affected, 821
trace-element therapy, 1243
Vascular
permeability, 1212
sensitivity to norepinephrine, 354
Vasoactive intestinal polypeptide content and neuropathy, 608

W

Welsh patients, susceptibility of non-insulin-dependent diabetes, 1479

Author Index

A

Aaen, K., 697
Aarslew-Jensen, M., 437
Abid, M., 534
Abumrad, N.A., 1228
Adezati, L., 796
Adi, S., 1569
Adkins-Marshall, B.A., 87
Aitken, P.M., 501
Akanuma, Y., 441, 528
Alberti, K.G.M.M., 390
Alejandro, R., 305
Alford, F.P., 501
Allen, T.J., 1182, 1575
Allison, T., 1550
Alvarez-Buylla, R., 1191
Amano, K., 590
Amiel, S., 134
Andersen, H.U., 204
Andersen, P.H., 865
Anderson, C.B., 515
Andoh, Y., 17
Andrews, K.M., 1414
Aoki, I., 1298
Aomine, M., 1485
Arita, M., 1485
Armour, J.C., 1519
Armstrong, G.R., 1347
Asahina, T., 1064
Asai, J., 639
Asano, T., 441
Assan, R., 768
Atkinson, M.A., 933
Atkinson, S.M., Jr., 1028
Awata, T., 266

B

Baba, S., 1070
Baba, T., 938
Bach, J.-F., 768, 1264
Bach, L.A., 557, 1182
Bagdade, J.D., 426
Bailey, C.J., 1289, 1326
Baird, A., 1002
Baird, J.D., 508, 1467
Bak, J.F., 865
Baker, L., 602
Balkan, B., 702
Ban, E., 1045
Barakat, H.A., 1527
Barbanti, M., 447
Barlascini, C.O., 1212
Baron, A.D., 955, 965

Barr, D., 142
Bascal, Z.A., 1347
Beattie, G.M., 1002
Becker, D.J., 1116
Beckerman, S., 1138
Bell, G.I., 123, 129
Bell, P.A., 1408
Benedetti, T.J., 234
Bennett, M.I., 757
Bennett, P.H., 1430
Benson, E.A., 549
Benzl, L., 844
Bergman, R.N., 1361
Bergstrom, R.W., 104
Bermúdez, M.C., 707
Berrios, J.P., 643
Berthault, M.-F., 734
Berti-Mattera, L.N., 782
Bertoli, E., 850
Bessho, H., 885
Best, J.D., 501
Betscholtz, C., 118
Bevilacqua, S., 383
Bhatnena, S., 1436
Bianchi, R., 782
Bierman, E.L., 1257
Bihoreau, M.-T., 734
Bishop, A., 1479
Biswas, S., 663
Björkman, O., 747
Björntorp, P., 570
Black, P.R., 62
Blackard, W.G., 1212
Blackman, J.D., 828
Blendis, L.M., 775
Bloom, S.R., 775
Boden, G., 1079
Boen, J.R., 1131
Boismare, F.A., 743
Boisson, C., 1264
Boitard, C., 768, 1264
Bonadonna, R., 383
Bone, A.J., 508, 1165, 1467
Bon, C., 383
Bonner-Weir, S., 401
Bonnet, B., 1451
Borgoglio, A., 796
Born, J., 1091
Bossoni, S., 1333
Botti, J.J., 914
Bougnères, P.-F., 1264
Bouillon, R., 477
Boulware, S.D., 1550
Braaten, J.T., 1353
Brandi, L.S., 383
Braunstein, S.N., 602
Brechtel, G., 22, 955, 965

Brichard, S.M., 1326
Brideau, C., 928
Brissonnette, L.G., 390
Britland, S.T., 898, 909
Brogren, C.-H., 697
Brucker, A.J., 602
Bruggink, J.E., 702
Brunetti, A., 844
Bryszewska, M., 241
Bu, B.-H., 752
Buchanan, W.E., 426
Buckley, D., 181
Buffington, C.K., 361
Bugawan, T.L., 96
Bunchman, T.E., 83
Burguera, B., 1490
Buscema, M., 397
Buschard, K., 697
Bushouse, S.A., 1131
Butler, P.C., 142, 217, 752, 1251, 1373
Buzzigoli, G., 383, 490
Bylander, J.E., 949

C

Calcutt, N.A., 663
Caldonazzo, A., 1333
Cameron, N.E., 460
Canadian-European Randomized Control Trial Group, 204
Caprio, S., 134, 1550
Carel, J.-C., 1264
Caro, J.F., 1028
Caroli, A., 740
Carpenter, C., 1138
Carpenter, J.W., 1527
Carpentier, J.-L., 924
Carroll, R.J., 871
Carter, W.B., 752
Carter, W.G., 31
Castellino, P., 38
Cecchetti, P., 844
Cédola, N.V., 707
Cerami, A., 1510
Ceriello, A., 447
Cerri, M., 490
Chakrabarti, S., 613, 657
Champagne, P., 653
Chandramouli, V., 456
Chang, D., 752
Chang, J.-K., 752
Chang, K., 323
Chantelau, E., 938
Charles, M.A., 1361
Charonis, A.S., 807

DIABETES: VOLUME 39 (1990) PAGE NUMBERS BY ISSUE

January, 1-128
February, 129-269
March, 271-399

April, 401-522
May, 523-645
June, 647-759

July, 761-877
August, 879-1007
September, 1009-1152

October, 1153-1314
November, 1315-1460
December, 1461-1587

AUTHOR INDEX 1990

Chartrel, N.C., 743
Chaussain, J.-L., 1264
Chen, C.-T., 175
Cherrington, A.D., 87
Chiba, T., 168, 875
Chick, W., 836
Chihara, K., 168
Chijiwa, Y., 608
Chinchilli, V.M., 675
Chonko, A.M., 1556
Chou, H.-F., 112
Chou, J., 752
Christie, M.R., 653
Christmansson, L., 18
Ciaraldi, T.P., 250
Ciccarone, A., 844
Cimino, A., 1333
Clabaut, M.T., 743
Clark, D.A., 1218
Clarke, B.E., 1575
Clarke, B.F., 898, 909
Clore, J.N., 1212
Cohen, D.K., 1408
Cohen, I.R., 1467
Coleman, D.L., 432
Colette, C., 1451
Collins, P.B., 626
Conover, C.A., 1251
Consoli, A., 211
Cooke, A., 508, 1467
Cooper, D.R., 181, 1399
Cooper, G.J.S., 260
Cooper, M., 175
Cooper, M.E., 1182, 1575
Copeland, E.J., 196
Cotter, M.A., 460
Cox, N., 1534
Cravarezzza, P., 1333
Craven, P.A., 667
Crawford, M.A., 914
Crepaldi, G., 57
Crisá, L., 1279
Cryer, P.E., 515
Cunnane, S.C., 775
Czech, M.P., 1279
Czernichow, P., 1045

D
Dahl, D.C., 1339
D'Alessio, D.A., 634, 1198
Danbury, B.H., 1218
Daneman, D., 653
Davidson, C.M., 667
Davis, M., 191
Davis, M.D., 1445
Deckert, T., 245
DeFrondo, R.A., 38
Dégano, P., 996
Dege, J.E., 807
De Hertoghe, R., 471
Del Favero, E., 57
Delovitch, T.L., 653

De Maria, R., 740
Demers, L.M., 914
DeMets, D.L., 1445
De Pascale, A., 796
De Pirro, R., 850
DeRubertis, F.R., 667
Devery, R.A.M., 626
Diabetes Epidemiology Research International Group, 858
Diem, P., 534
Diemer, N.H., 437
Dills, D.G., 191
DiMarchi, R., 1028
Doerrler, W., 1569
Dohm, G.L., 1028
Dohmen, C., 938
Donadon, V., 289
Dorman, J.S., 1116
Dowse, G.K., 390
Doyle, A.E., 1575
Drash, A.L., 1116, 1585
Drejer, K., 1033
Drummer, C., 369
Duckworth, W.C., 1339
Duell, P.B., 1257
Duhamel, D., 928
Dunham, T., 541
Du Rostu, H., 768

E
Eades, D.M., 312, 323
Easteal, S., 855
Edelman, S.V., 955, 965
Efendić, S., 340, 456
Efrat, S., 406
Egawa, H., 466
Eggler, J.R., 1218
Eichberg, J., 782, 1498
Einhorn, T.A., 477
Eisenbarth, G.S., 879
Elias, D., 1467
Ellis, D., 1116
Elton, C.W., 1028
Engström, U., 118
Ensink, J.W., 634, 1198
Epand, R.M., 241
Eriksson, G.L., 276
Eriksson, L.S., 747
Eriksson, U.J., 276
Erlich, H.A., 96
Ezaki, O., 1543

F
Faglia, E., 740
Faierman, E., 477
Faloia, E., 850
Falqui, L., 515
Fan, M.-Y., 519
Fareed, D., 390
Farese, R.V., 181, 1399

Farrell, C.R., 1040
Faucher, M., 1099
Favales, F., 740
Fedele, D., 57
Fehm, H.L., 1091
Feingold, K.R., 1569
Ferguson, R.M., 1235
Ferrannini, E., 383, 490
Feutren, G., 768
Figoni, M., 768
Finch, C.F., 390
Fioretto, P., 289
Fiori, M.G., 782
Fitch, F.W., 815
Flecha, F.L.G., 707
Flickinger, E.G., 1028
Flier, J.S., 712, 865
Flood, J.F., 1391
Floyd, B., 87
Flye, M.W., 515
Flynn, T., 149
Foggensteiner, L., 1165
Foley, J.E., 1408
Frament, N., 1264
Frank, B.H., 1339
Fratkin, M.J., 1212
Freidenberg, G.R., 250
Freinkel, N., 575
French, L.R., 1131
Frölich, M., 333
Fröschl, H., 369
Fu, X.-W., 519
Fujimoto, W.Y., 104, 634
Fujita, T., 168, 875
Fukase, M., 168
Fukuda, N., 1543
Fumelli, P., 850
Furcht, L.T., 807

G
Gabbay, K.H., 1504
Gagliardino, J.J., 707
Garcia-Palmer, F.-J., 575
Gareeboo, H., 390
Garner, M.H., 1472
Gatta, C., 397
Gauguier, D., 734
Gavin, J.R., III, 1106
Gelfand, R.A., 134
Geloni, M., 383
Gerhardinger, C., 57
Gerich, J.E., 211, 1381
Ghahary, A., 657
Ghosh, A., 1305
Giacca, A., 340
Giaccari, A., 1243
Gibbs, E.M., 1218, 1414
Gingerich, R.L., 515
Ginsberg-Fellner, F., 1138, 1203
Giorato, C., 289
Giugliano, D., 447
Giustina, A., 1333
Giustina, G., 1333

DIABETES: VOLUME 39 (1990) PAGE NUMBERS BY ISSUE

January, 1-128	April, 401-522	July, 761-877	October, 1153-1314
February, 129-269	May, 523-645	August, 879-1007	November, 1315-1460
March, 271-399	June, 647-759	September, 1009-1152	December, 1461-1587

Given, B.D., 175
 Givens, J.R., 361
 Goetz, F.C., 1131
 Gorden, D.L., 924
 Gottlieb, P.A., 643
 Gough, D.A., 1519
 Gowen, B., 483
 Green, I.C., 1289
 Greenbaum, C.J., 549
 Greenberg, R.E., 541
 Greene, D.A., 613
 Greiner, D.L., 643, 836, 1279
 Griffith, R.L., 96
 Grill, V.E., 1581
 Grodsky, G.M., 871
 Gronda, E., 740
 Grose, M., 1099
 Grunfeld, C., 1569
 Grunwald, J.E., 602
 Guarner, V., 1191
 Gumbiner, B., 22, 149
 Gunn, S., 1504
 Gupta, R., 340

H

Habener, J.F., 406
 Haffner, S.M., 283
 Hall, K., 340
 Hall, K.L., 1218
 Hamaguchi, K., 415
 Hanahan, D., 406
 Handler, E.S., 643, 836, 1279
 Haour, F., 1045
 Harrington, B., 891
 Hartnell, J.M., 348
 Harvey, J.N., 299
 Hashimoto, T., 1561
 Haskins, K., 1366
 Hassell, J.R., 196
 Hatamori, N., 1070
 Hattoni, Y., 17
 Hayek, A., 1002
 Haymond, M.W., 217
 Hazuda, H.P., 283
 Heath, J., 1527
 Hebdon, R.A., 483
 Helqvist, S., 204
 Hendrick, G.K., 87
 Hennes, M.M.I., 789
 Henquin, J.-C., 1326, 1457
 Henry, M.L., 1235
 Henry, R.R., 22, 149
 Hernandez, H., 181
 Herold, K.C., 815
 Herrmberger, S., 938
 Herron, K.G., 1556
 Hirai, K.-I., 563
 Hiraishi, S., 983
 Hisatomi, A., 608
 Ho, R.S., 1408
 Holland, G.F., 1218

Holloszy, J.O., 1425
 Hommel, E., 1057
 Horn, T., 697
 Hors, J., 768
 Hostetter, M.K., 271
 Hougaard, P., 1033
 Hunt, J.V., 1420
 Hutson, N.J., 1218, 1414

I

Ibayashi, H., 608
 Ido, Y., 690
 Ihm, S.-H., 1273
 Ikekuchi, M., 1064
 Ikeda, H., 1050
 Imura, H., 1050
 Inoue, S., 1298
 Inui, T., 168
 Ipp, E., 112
 Ishii, H., 983
 Ishii, H., 1561
 Ishizuka, T., 181
 Itakura, H., 1543
 Iwamoto, Y., 266
 Iwasima, Y., 983

J

Jackson, B., 1182
 Jaffa, A.A., 299
 Jaffe, A.S., 515
 Jakobsen, J., 437
 James, D.E., 1425
 James, R.W., 1158
 Jarett, L., 683
 Jean-Didier, N., 1361
 Jenkins, D.J.A., 775
 Jenkins, M., 775
 Jensen, T., 245
 Jansson, T., 211, 1381
 Jerums, G., 557, 1182, 1575
 Johnson, A.H., 626
 Johnson, J.D., 541
 Johnson, K.H., 118
 Johnson, T.M., 757
 Johnson, W.T., 619
 Jones, T.W., 1550
 Jordan, K., 118
 Jørgensen, H.E., 1057
 Jøsøe, K., 697
 Josse, R.G., 775
 Juji, T., 266

K

Kadowaki, S., 168
 Kahn, B.B., 712, 865
 Kahn, S.E., 549, 634
 Kaku, K., 49

Kalbfleisch, J., 891
 Kamijo, M., 690
 Kanazawa, Y., 266
 Kang, Y.S., 563
 Kangawa, K., 639
 Karjalainen, J.K., 1144
 Karl, I.E., 1106
 Karounos, D.G., 1085
 Kashiwagi, A., 1064
 Kasuga, M., 528
 Kawai, K., 1320
 Kazama, M., 983
 Kelley, D., 211, 1381
 Kennedy, W.R., 802
 Kenyon, N.S., 305
 Kern, W., 1091
 Kerner, W., 1091
 Khan, A., 456
 Khandelwal, R.L., 821
 Khawaja, X.Z., 1289
 Khazanie, P., 1527
 Kienast, S.G., 942
 Kikuoka, H., 885
 Kilo, C., 312, 323
 Kim, Y., 83
 Kinlough-Rathbone, R.L., 241
 Kisselbach, A.H., 789
 Kitabchi, A.E., 361
 Klaff, L.J., 549, 720
 Klein, B.E.K., 191, 1445
 Klein, R., 191, 1445
 Klein-Robbenhaar, E., 1243
 Klöppel, G., 720
 Knopp, R.H., 234
 Knowler, W.C., 1430
 Kodama, M., 1064
 Koh, G., 1050
 Kohonen-Corish, M.R.J., 855
 Koivisto, V.A., 157
 Koranyi, L., 1534
 Kosho, O., 528
 Kouzi-Koliakos, K., 807
 Kraemer, D., 1550
 Krans, H.M.J., 333
 Kreutter, D.K., 1218, 1414
 Krupp, M.N., 1218
 Kryshak, E.J., 142, 217, 1373
 Ktorza, A., 734
 Kuhn, D.C., 914
 Kuller, L.H., 1116
 Kuzava, J.E., 432
 Kuzuya, T., 266

L

Laakso, M., 955, 965
 Laborie, C., 768
 Lacy, P.E., 323, 515
 Lardais, P., 1264
 Landau, B.R., 456
 Landgraf, R., 369
 Landgraf-Leurs, M.M.C., 369

DIABETES: VOLUME 39 (1990) PAGE NUMBERS BY ISSUE

January, 1-128
 February, 129-269
 March, 271-399

April, 401-522
 May, 523-645
 June, 647-759

July, 761-877
 August, 879-1007
 September, 1009-1152

October, 1153-1314
 November, 1315-1460
 December, 1461-1587

Lapolla, A., 57
 LaPorte, R.E., 1116
 Lappi, D.A., 1002
 Lauzon, J., 583
 Law, W.R., 62
 Leahy, J.L., 401
 Ledbetter, S., 196
 Lee, P.D.K., 1251
 Lefebvre, P., 447
 Leggett, N., 1527
 Leighton, B., 260
 Leiter, E.H., 415, 432
 Leonetti, D.L., 104
 Lernmark, Å., 720
 LeRoith, D., 1490
 Levesque, L., 519
 Levy, J., 1106
 Levy, R.A., 426
 Lewis, G.F., 828
 Lickley, L., 340
 Lieb, K., 1091
 Lieberman, I., 1585
 Lin, J.-L., 441
 Lipes, M.A., 879
 Lodish, H.F., 712
 Loewenson, R.B., 802
 Loftfield, R.B., 541
 Løkkegaard, H., 1057
 Lönroth, P., 570
 Loon, N., 76
 LoPachin, R.M., Jr., 1498
 Loria, R.M., 675
 Löw, H., 456
 Lowery, J.M., 1498
 Loy, A., 1305
 Lozano, J., 1361
 Luchetta, R., 933, 975
 Lucisano, J.Y., 1519
 Lum, Z.-P., 519
 Lund, S., 865
 Lurie, K.G., 1305
 Luzi, L., 38
 Luzio, S.D., 1479

M
 Ma, X.Y., 938
 MacDonald, M.J., 1461
 MacDonald, R.G., 1279
 MacDougall, M.L., 1556
 MacGregor, L.C., 1305
 McLaren, N.K., 933
 Magee, M.S., 234
 Magnuson, M.A., 523
 Makino, I., 983
 Maling, T.J.B., 1177
 Malpas, S.C., 1177
 Mandarino, L., 211
 Mandrup-Poulsen, T., 204
 Mangiavacchi, M., 740
 Mantero, F., 289
 Marchetti, P., 515, 844
 Marchi, E., 447

Marco, J., 996
 Margolius, H.S., 299
 Mariani, G., 643
 Markholst, H., 720
 Marks, R., 1527
 Marliis, E.B., 1099
 Marsh, C., 142
 Marsh, M., 1373
 Martinez, A.M., 1131
 Maser, R.E., 1116
 Masuda, M., 466
 Mathiesen, E.R., 245
 Matschinsky, F.M., 647, 1305
 Matsuda, A., 266
 Matsukura, S., 639
 Matsumoto, E., 885
 Matsumoto, G., 885
 Matsuo, H., 639
 Matsuo, T., 1050
 Matsutani, A., 49, 1534
 Mauer, S.M., 83
 Mauritius Noncommunicable Disease Study Group, 390
 Mauseeth, R.S., 549
 Mayfield, R.K., 299
 Mazzanti, L., 850
 Mazzola, E., 740
 McCarthy, G., 1550
 McCulloch, D.K., 549
 McCullough, C.S., 515
 McCune, S.A., 789
 McEvoy, R.C., 1138, 1203
 McIntosh, R.H., 1408
 McKean, B.D., 1519
 McLane, M.P., 62
 McLendon, V.D., 1527
 McNeill, J.H., 483
 McPherson, R.K., 1218
 Mealing, G.A.R., 1353
 Meisler, M.H., 757
 Métroz-Dayer, M.-D., 928, 1099
 Meyer, S.M., 815
 Meyer, T.W., 76, 989
 Michiels, B., 471
 Miller, A., 142
 Miller, P.L., 989
 Mintz, D.H., 1585
 Miralles, P., 996
 Miralles, D.J., 690
 Mitchell, B.D., 283
 Mitrakou, A., 211, 1381
 Mitsukawa, T., 639
 Mitsuyama, S., 1170
 Miwa, I., 1170
 Miyaji, T., 17
 Miyajima, E., 1125
 Miyamura, K., 885
 Mogensen, C.E., 761
 Mohan, P.S., 31
 Mojsov, S., 406
 Molina, J.M., 250, 260
 Mollen, N., 1138
 Moller, D.E., 865
 Mølvig, J., 204

Moncada, V.Y., 924
 Mondon, C.E., 1425
 Monier, L., 1451
 Montag, A.G., 815
 Montambault, M., 1099
 Montgomery, L.B., 675
 Mooney, N.T., 1028
 Mooradian, A.D., 348, 1391
 Moore, W.V., 1556
 Mordes, J.P., 643, 720, 836, 1279
 Morelli, E., 76
 Morff, R.J., 354
 Morgan, R., 1479
 Morishita, T., 168, 875
 Morley, J.E., 1391
 Morocutti, A., 289
 Moser, A., 1569
 Moss, S.E., 191, 1445
 Mott, D.M., 1430
 Mouland, A., 928
 Mueckler, M., 6, 49
 Mühlhauser, J., 924
 Mukai, H., 1320
 Munck, M., 204
 Murakami, T., 466
 Murase, N., 1585
 Murata, K., 466
 Murata, T., 1170
 Murayama, Y., 1320
 Murphy, L.J., 657
 Murtaugh, M., 118
 Mustard, J.F., 241
 Myers, B.D., 76
 Myers, S.R., 87

N
 Nadelson, J., 1408
 Nagamatsu, S., 871
 Nagata, M., 1070
 Nair, G., 1399
 Nair, K.S., 376
 Nakajima, S., 1298
 Nakamura, A., 168
 Nakamura, N., 836
 Nakashima, K., 17
 Nakazato, M., 639
 Nalesnik, M.A., 1585
 Nanjo, K., 885
 Natali, A., 490
 Navalesi, R., 844
 Navarro, X., 802
 Nawata, H., 608, 1561
 Nedergaard, M., 437
 Nelson, R.G., 1430
 Nepom, G.T., 96, 549, 1153
 Nestler, J.E., 1212
 Newell-Morris, L.L., 104
 Nijs, H.G.T., 333
 Nishio, Y., 1064
 Nobe, S., 1485
 Noda, K., 608
 Nonaka, K., 1125

DIABETES: VOLUME 39 (1990) PAGE NUMBERS BY ISSUE

January, 1-128	April, 401-522	July, 761-877	October, 1153-1314
February, 129-269	May, 523-645	August, 879-1007	November, 1315-1460
March, 271-399	June, 647-759	September, 1009-1152	December, 1461-1587

Noonan, D., 196
 Nosadini, R., 289
 Nowak, T.V., 891
 Nurjhan, N., 211
 Nyberg, B., 747

O

Obata, M., 975
 O'Brien, R.C., 1182, 1575
 O'Brien, T.D., 118
 Ocana, A.M., 775
 Odatti, P.R., 796
 O'Dorisio, T.M., 1235
 Ogawa, T., 1064
 Ohashi, S., 1320
 Oikawa, S., 12
 Oka, Y., 441
 Okamoto, T., 12
 Okuda, J., 1170
 Okuda, K., 1298
 Okuyama, M., 266
 Oiefsky, J.M., 250, 260, 955, 965, 1009
 Oleggini, M., 383
 O'Meara, N.M.G., 626
 Ono, H., 608
 Ooshima, A., 885
 Ooshima, E., 983
 Opocher, G., 289
 Oram, J.F., 1257
 Orchard, T.J., 1116
 Ortaldo, J., 836
 Osei, K., 597, 1235
 Östenson, C.-G., 456
 Østerby, R., 1057
 Owen, O.E., 450
 Owens, D., 626
 Owens, D.R., 1479
 Owerbach, D., 1504

P

Packard, C.J., 1017
 Packham, M.A., 241
 Palmer, J.P., 549, 720
 Pampfer, S., 471
 Pangburn, T., 1381
 Papazoglou, D., 1575
 Pardridge, W.M., 1040
 Park, S.K., 989
 Parving, H.-H., 1057
 Pascoe, W.S., 226
 Patterson, J.K., 283
 Pedersen, O., 865
 Pedrinelli, R., 490
 Peiró, E., 996
 Pelletier, D., 1228
 Pelli, B., 57
 Perico, N., 289
 Perkins, J.D., 142
 Permutt, M.A., 49, 1534

Peters, J.R., 1479
 Peters, W., 76
 Petersen, H., 697
 Petrides, A.S., 38
 Petrig, B.L., 602
 Pettitt, D.J., 1430
 Philippot, J.R., 1451
 Phillips, T.M., 728
 Picon, L., 734
 Pizzi, G., 740
 Polak, M., 1045
 Pollet, R.J., 1399
 Polonsky, K.S., 142, 175, 828
 Pometta, D., 1158
 Pories, W.J., 1028
 Porte, D., Jr., 634
 Postel-Vinay, M.C., 1045
 Poussier, P., 928
 Powell, A.M., 1436
 Powers, A.C., 406
 Province, M.A., 312, 323
 Pugazhenthi, S., 821
 Pugliese, G., 312, 323
 Purrello, F., 397

Q

Qin, H.-Y., 583
 Quatraro, A., 447

R

Rabini, R.A., 850
 Rabkin, R., 1339
 Raccah, D., 1361
 Radder, J.K., 333
 Radoff, S., 1510
 Raju, M.S., 1028
 Rand, M.L., 241
 Ratner, R.E., 728
 Raymond, R.M., 62
 Recant, L., 1436
 Redmon, J.B., 534
 Rees, A., 1479
 Regen, D.M., 1228
 Reger, L.A., 807
 Reichard, G.A., Jr., 450
 Reilly, J., 211, 1381
 Remuzzi, G., 289
 Ren, J.M., 157
 Reynolds, C.W., 836
 Ribel, U., 1033
 Rich, S.S., 1006, 1315
 Ritter, M.C., 426
 Riva, C.E., 602
 Rizza, R.A., 142, 217, 752, 1251, 1373
 Robert, A., 924
 Roberts, C.T., Jr., 1490
 Roberts, E.F., 619

Robertson, R.P., 534
 Robertson, S., 460
 Rocco, S., 289
 Rodier, M., 768
 Rodnick, K.J., 1425
 Roessler, E., 1550
 Rolandi, R., 796
 Romanelli, G., 1333
 Rønn, B., 245
 Rorsman, F., 118
 Rossetti, L., 1243
 Rossi, J.P.C., 707
 Rossini, A.A., 643, 836, 1279
 Rostain-Capillaon, O., 1451
 Rubenstein, P., 1138
 Rygaard, J., 697

S

Saad, M.F., 1430
 Sadelain, M.W.J., 583
 Sahlin, K., 157
 Sainte-Marie, J., 1451
 Sako, Y., 1581
 Santarelli, E., 312
 Santiago, J.V., 515
 Santoro, D., 490
 Sato, H., 563
 Sato, T., 983
 Saubermann, A.J., 1498
 Scharf, S., 96
 Scharfmann, R., 1045
 Scharp, D.W., 515
 Schoenfeld, S.L., 549
 Schrub, J.-C., 743
 Schwartz, J.-L., 1353
 Schwartz, M.W., 634
 Schwartz, S.S., 602
 Schwenk, W.F., 217
 Seino, M., 123, 129
 Seino, S., 123, 129
 Seino, Y., 1050
 Selam, J.-L., 1361
 Semplicini, A., 289
 Sens, D.A., 949
 Serjeantson, S.W., 855
 Shapiro, E.T., 175
 Sharma, A.K., 898, 909
 Shaw, W.N., 619
 Shechter, Y., 1
 Shen-Orr, Z., 1490
 Shepherd, J., 1017
 Sherman, W.R., 312
 Sherwin, R.S., 134, 1550
 Shewey, L., 549
 Shibasaki, Y., 441
 Shigenaga, J., 1569
 Shigeta, Y., 1064
 Shii, K., 1070
 Shimpo, K., 975
 Shrago, E., 789

DIABETES: VOLUME 39 (1990) PAGE NUMBERS BY ISSUE

January, 1-128
 February, 129-269
 March, 271-399

April, 401-522
 May, 523-645
 June, 647-759

July, 761-877
 August, 879-1007
 September, 1009-1152

October, 1153-1314
 November, 1315-1460
 December, 1461-1587

AUTHOR INDEX 1990

Shuman, W.P., 104
Silvestre, R.A., 996
Sima, A.A.F., 613
Simonson, D.C., 38
Singer, W., 775
Singh, B., 583
Sirmai, J., 768
Skipper, B.J., 541
Skottner, A., 340
Skutches, C.L., 450
Slieker, L.J., 619
Smith, C.C.T., 1420
Smith, R.M., 683
Smith, U., 570
Solomon, D., 1436
Sommer, B.G., 1235
Sørensen, A.R., 1033
Soued, M., 1569
Spector, D., 406
Speedy, A., 312, 323
Spinias, G.A., 204
Spire, J.-P., 828
Spiro, R.G., 31
Sprafka, J.M., 1131
Squatrito, S., 844
Stackhouse, S., 989
Standaert, M., 181, 1399
Stannard, B., 1490
Staprans, I., 1569
Starick-Zych, K., 1550
Starzl, T.E., 1585
Stecha, P., 1366
Steffens, A.B., 702
Steger, R.W., 942
Steiner, D.F., 571
Steiner, M., 728
Steinhuber, R., 369
Stern, M.P., 283
Stevenson, R.W., 1218, 1414
Storlien, L.H., 226
Storm, B., 245
Storrie, M.C., 348
Strasser, S., 305
Strubbe, J.H., 702
Stuart, M.J., 914
Sturaro, A., 57
Subbiah, P.V., 426
Suci-Foca, N., 1138
Suiker, A.M.H., 477
Sun, A.M., 519
Supon, P., 1366
Sutherland, D.E.R., 534, 802
Suzuki, S., 1320
Svedberg, J., 570
Swenne, I., 70

T

Taborsky, G.J., Jr., 634
Taddei, S., 490
Tafuri, A., 836
Tai, I.T., 519
Tait, B., 96

Takaku, F., 441, 528
Takamura, Y., 1298
Takechi, M., 17
Takemura, J., 639
Tamborlane, W.V., 134, 1550
Taminato, T., 1050
Tanaka, S.-I., 1298
Tang, C., 483
Tappy, L., 1079
Tashiro-Hashimoto, Y., 528
Taskinen, M.-R., 1017
Taylor, S.I., 924
Tehrani, S.T., 1472
Tesi, R.J., 1235
Tetrault, G.A., 1212
Thies, R.S., 250
Thomas, C.R., 276
Thomas, J.W., 1085
Thomas, N.M., 1203
Thomasset, M., 477
Thorburn, A.W., 22, 149
Thorens, B., 712
Thorpe, J.R., 1289
Tilton, R.G., 312, 323
Timmers, K.I., 1436
Tito, J., 376
Tobe, K., 528
Todd, M.E., 483
Todo, S., 1585
Tomkin, G.H., 626
Tomlinson, D.R., 663
Towle, V.L., 828
Toyota, T., 12
Traldi, P., 57
Trappe, P., 938
Trevisan, R., 289
Triebwasser, K., 87
Triguero, D., 1040
Trischitta, V., 844
Tsao, T., 1339
Tsilibary, E.C., 807
Tsuda, K., 1050
Tsui, A., 563
Tsukuda, K., 441
Tucker, B.J., 919
Tuomilehto, J., 390

U

Umeda, F., 608, 1561
Usami, M., 1050

V

Vague, P., 768
Vanderheyden, I., 471
Van Herck, E., 477
Varey, A.-M., 508
Veneman, T., 211, 1381
Vercheval, M., 471
Verhaeghe, J., 477
Verma, S.P., 1451

Vetri, M., 397
Vexiau, P., 768
Vigneri, R., 397, 844
Vila, M.C., 1399
Vinci, C., 397
Visser, W.J., 477
Vlassara, H., 1510
Vogel, L.R., 1243
Vogeli, G., 196
Volkmann, R.A., 1218
Von Schacky, C., 369
Voyles, N.R., 1436
Vranic, M., 340
Vuksan, V., 775

W

Wahl, P.W., 104
Wahren, J., 747
Walker, M., 1138
Walker, R., 508
Wallace, P., 955, 965
Walters, J.M., 501
Wang, M., 1251
Wang, Y.-N., 752
Ward, G.M., 501
Watala, C., 241
Watanabe, K., 983
Watson, J.E., 1399
Webster, K.A., 1165
Weide, L.G., 515
Weigensberg, M.J., 575
Weir, G.C., 401
Welle, S.L., 376
Werner, H., 1490
Westermark, P., 118
Whitesell, R.R., 1226
Whitfield, J.F., 1353
Wiegmann, T.B., 1556
Wilkin, T.J., 1165
Wilkins, S.D., 1436
Williams, P.E., 87
Williamson, J.R., 312, 323
Willsky, G.R., 757
Wilson, J.M., 1305
Winocour, P.D., 241
Winter, W.E., 975
Woda, B.A., 836
Wogenrich, F.J., 541
Wohlhueter, R.M., 807
Wojcikowski, C., 815
Wolever, T.M.S., 775
Wolff, S.P., 1347, 1420
Wong, G.S., 775
Wooliard, A.C.S., 1347

Y

Yagihashi, S., 690
Yamada, K., 975, 1125
Yamaguchi, A., 168, 875

DIABETES: VOLUME 39 (1990) PAGE NUMBERS BY ISSUE

January, 1-128
February, 129-269
March, 271-399

April, 401-522
May, 523-645
June, 647-759

July, 761-877
August, 879-1007
September, 1009-1152

October, 1153-1314
November, 1315-1460
December, 1461-1587

AUTHOR INDEX 1990

Yamamoto, J.J., 1472
Yamamoto, T., 1050
Yamashita, K., 1320
Yamatani, Y., 168
Yamazaki, K., 17

Yki-Järvinen, H., 157
Yokono, K., 1070
Yoon, J.-W., 590, 1273
Young, D.A., 1408
Young, R.J., 898, 909

Z

Zaina, M.S., 740
Zanette, G., 289
Zhang, W.-X., 613
Zimmet, P.Z., 390, 855

DIABETES: VOLUME 39 (1990) PAGE NUMBERS BY ISSUE

January, 1-128
February, 129-269
March, 271-399

April, 401-522
May, 523-645
June, 647-759

July, 761-877
August, 879-1007
September, 1009-1152

October, 1153-1314
November, 1315-1460
December, 1461-1587

